NEO212 + carboplatin + paclitaxel

This agent is a **combination regimen** of three drugs: - **NEO212** is a novel conjugate of temozolomide (an oral DNA-alkylating agent) with perillyl alcohol (a monoterpene with antitumor properties). It exerts cytotoxic and differentiation-inducing effects on cancer cells, including those resistant to standard chemotherapy, by forcing them to differentiate and undergo growth arrest and death. Its mechanisms include DNA methylation leading to apoptosis and possible induction of macrophage differentiation, and it is being developed for brain tumors and acute myeloid leukemia. - **Carboplatin** is a platinum-based chemotherapeutic agent that induces DNA cross-linking and triggers apoptosis in rapidly dividing cancer cells. - **Paclitaxel** is a microtubule-stabilizing agent that disrupts mitosis by preventing microtubule disassembly, leading to cell cycle arrest and apoptosis in cancer cells. This combination regimen is under investigation for the treatment of various cancers, including brain tumors and possibly other solid tumors, leveraging complementary mechanisms of action to enhance antitumor efficacy and overcome resistance.

Other names

NEO212 + carboplatin + paclitaxel